Patents Assigned to Austin and Repatriation Medical Centre
-
Patent number: 7931907Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: October 6, 2008Date of Patent: April 26, 2011Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health ServiceInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
-
Publication number: 20090155771Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: ApplicationFiled: October 6, 2008Publication date: June 18, 2009Applicants: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health ServiceInventors: Angeline Ingrid BARTHOLOMEUSZ, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
-
Patent number: 7431933Abstract: The present invention relates generally to viral variants exhibiting reduced sensitivity to agents and in particular nucleoside analogues. More particularly, the present invention is directed to hepatitis B virus variants exhibiting complete or partial resistance to nucleoside analogues. The variants may also comprise corresponding mutations affecting immunological interactivity to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes and in developing new or modified vaccines directed against viral agents and in particular hepatitis B virus variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.Type: GrantFiled: June 8, 2001Date of Patent: October 7, 2008Assignees: Melbourne Health, Austin and Repatriation Medical Centre, Central Sydney Area Health ServiceInventors: Angeline Ingrid Bartholomeusz, Stephen Alister Locarnini, Anna Ayres, Margaret Rose Littlejohn, Geoffrey William McCaughan, Peter William Angus
-
Patent number: 7129379Abstract: Compounds of formula (Ia) as potent, ?1-specific beta blockers with a short duration of action in the systemic circulation, wherein R is 3?,4?-dimethoxyphenyl, R1 is hydrogen, and R2 is selected from methyl, ethyl, propyl, isobutyl and isopropyl; or R is 3?,4?-dimethoxyphenyl, R1 is selected from fluorine, chlorine and bromine, and R2 is selected from methyl, ethyl, propyl, isopropyl, isobutyl and cyclopropylmethyl; of R is 4?-methoxyphenoxy, R1 is selected from hydrogen, fluorine, chlorine and bromine, and R2 is selected from methyl, ethyl, propyl, isopropyl, isobutyl and cyclopropylmethyl; or R is 3?,4?-dimethoxyphenyl, R1 is cyano, and R2 is cyclopropylmethyl; or R is 4?-methoxyphenoxy, R1 is cyano, and R2 is isobutyl; and physiologically acceptable hydrolysable derivatives thereof having the hydroxy group in the 2-position of the 3-aminopropoxy side chain in esterified form, in their racemic and optically active forms, and their pharmaceutically acceptable acid addition salts.Type: GrantFiled: April 14, 2003Date of Patent: October 31, 2006Assignee: William John Louis, Austin and Repatriation Medical CentreInventors: William John Louis, Graham Paul Jackman, Dimitrios Iakovidis, Simon Nicholas Stewart Louis, Olaf Heino Drummer
-
Patent number: 6627662Abstract: Compounds of formula (Ia) as potent, &bgr;1-specific beta blockers with a short duration of action in the systemic circulation, wherein R is 3′,4′-dimethoxyphenyl.Type: GrantFiled: September 21, 1999Date of Patent: September 30, 2003Assignee: William John Louis, Austin and Repatriation Medical CentreInventors: William John Louis, Graham Paul Jackman, Dimitrios Iakovidis, Simon Nicholas Stewart Louis, Olaf Heino Drummer